FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Cramer: Investors, Don’t Do This
- On Wednesday's Mad Money: Costco & Cypress Semi CEOs
- Lightning Round: Toyota, Ford, Colgate-Palmolive and More
- Lightning Round OT: Hudson City Bancorp, Duke Energy and More
- Is This the Next 3Com?
- John Mack: Hero of the Credit Crisis?
- Cramer: Buy This New Gold ETF
- Cramer Tackles Toll Brothers Report
- Lightning Round: Priceline.com, Citigroup, Transocean and More
- Lightning Round OT: STEC, ICICI Bank and More
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
Caution is king, Cramer declared during Monday's Mad Money. So only the best stocks will work in this troubled market.
Today, Cramer listed his four criteria for buying: only on an "oversold rally," in a "crescendo sell-off," if the stock has more than a 4% dividend or it's a consistent earnings deliverer with a catalyst on the horizon. Genentech [DNA
Loading...
()
], he said, is a good example of this last point.
The biotech company has the best growth, the least cost and the most potential for estimate increases, Cramer said. And Genentech has an analyst meeting this Friday, March 14, that should bring some good news for investors.
What could happen? Avastin sales could be better than expected. Genentech could raise its earnings forecast or pre-announce its Q1 results. Maybe DNA will raise its long-term goals higher than the 25% annual earnings per share growth the company's expecting. There could be news about an upcoming drug trial, too.
Whatever it is the company announces Friday, most likely it's just going to make this great stock better, Cramer said.
Cramer recommended DNA at $73.78, the stock closed at $78.21 Monday, and he said it could reach $100 over the next 12 months.
Oh, and there's another reason Genentech works. Biotech was the strongest group during the difficult 1990 market, which had many of the same problems we have now. Cramer said he thinks the sector, and DNA in particular, can work again.
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes